APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antidiabetic Biguanides

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Antidiabetic Biguanides Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025190 pages

Choose your research edition.

Industry ResearchAntidiabetic Biguanides Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Antidiabetic Biguanides Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Antidiabetic Biguanides Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antidiabetic Biguanides Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Antidiabetic Biguanides Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Antidiabetic Biguanides market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Antidiabetic Biguanides is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antidiabetic Biguanides is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antidiabetic Biguanides is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Antidiabetic Biguanides is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Antidiabetic Biguanides include Boehringer Ingelheim, Bristol-Myers Squibb, Novo Nordisk, Servier Laboratories, AstraZeneca, GlaxoSmithKline, Pfizer, Eli Lilly and Merck & Co, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Antidiabetic Biguanides market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antidiabetic Biguanides and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antidiabetic Biguanides sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Antidiabetic Biguanides market size, projected growth trends, production technologies, key applications, and end-use industries.

Antidiabetic Biguanides Segment by Company

Boehringer Ingelheim

Bristol-Myers Squibb

Novo Nordisk

Servier Laboratories

AstraZeneca

GlaxoSmithKline

Pfizer

Eli Lilly

Merck & Co

Sanofi

Takeda Pharmaceuticals

Antidiabetic Biguanides Segment by Type

Metformin IR

Metformin SR

Antidiabetic Biguanides Segment by Application

Hospitals

Clinics

Other

Antidiabetic Biguanides Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antidiabetic Biguanides market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antidiabetic Biguanides and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antidiabetic Biguanides.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Antidiabetic Biguanides market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Antidiabetic Biguanides manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Antidiabetic Biguanides in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Antidiabetic Biguanides in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Antidiabetic Biguanides Industry Trends Table 2. Antidiabetic Biguanides Industry Drivers Table 3. Antidiabetic Biguanides Industry Opportunities and Challenges Table 4. Antidiabetic Biguanides Industry Restraints Table 5. Global Antidiabetic Biguanides Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Antidiabetic Biguanides Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Antidiabetic Biguanides Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Antidiabetic Biguanides Sales Market Share by Manufacturers Table 9. Global Antidiabetic Biguanides Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Antidiabetic Biguanides Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Antidiabetic Biguanides Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Antidiabetic Biguanides Manufacturers, Product Type & Application Table 13. Global Antidiabetic Biguanides Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Antidiabetic Biguanides by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Metformin IR Table 17. Major Manufacturers of Metformin SR Table 18. Global Antidiabetic Biguanides Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Antidiabetic Biguanides Sales by Type (2021-2026) & (K Units) Table 20. Global Antidiabetic Biguanides Sales by Type (2027-2032) & (K Units) Table 21. Global Antidiabetic Biguanides Sales Market Share by Type (2021-2026) Table 22. Global Antidiabetic Biguanides Sales Market Share by Type (2027-2032) Table 23. Global Antidiabetic Biguanides Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Antidiabetic Biguanides Revenue by Type (2021-2026) & (K Units) Table 25. Global Antidiabetic Biguanides Revenue by Type (2027-2032) & (K Units) Table 26. Global Antidiabetic Biguanides Revenue Market Share by Type (2021-2026) Table 27. Global Antidiabetic Biguanides Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospitals Table 29. Major Manufacturers of Clinics Table 30. Major Manufacturers of Other Table 31. Global Antidiabetic Biguanides Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Antidiabetic Biguanides Sales by Application (2021-2026) & (K Units) Table 33. Global Antidiabetic Biguanides Sales by Application (2027-2032) & (K Units) Table 34. Global Antidiabetic Biguanides Sales Market Share by Application (2021-2026) Table 35. Global Antidiabetic Biguanides Sales Market Share by Application (2027-2032) Table 36. Global Antidiabetic Biguanides Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Antidiabetic Biguanides Revenue by Application (2021-2026) & (K Units) Table 38. Global Antidiabetic Biguanides Revenue by Application (2027-2032) & (K Units) Table 39. Global Antidiabetic Biguanides Revenue Market Share by Application (2021-2026) Table 40. Global Antidiabetic Biguanides Revenue Market Share by Application (2027-2032) Table 41. Global Antidiabetic Biguanides Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Antidiabetic Biguanides Sales by Region (2021-2026) & (K Units) Table 43. Global Antidiabetic Biguanides Sales Market Share by Region (2021-2026) Table 44. Global Antidiabetic Biguanides Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global Antidiabetic Biguanides Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Antidiabetic Biguanides Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America Antidiabetic Biguanides Sales by Country (2021-2026) & (K Units) Table 48. North America Antidiabetic Biguanides Sales by Country (2027-2032) & (K Units) Table 49. Europe Antidiabetic Biguanides Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe Antidiabetic Biguanides Sales by Country (2021-2026) & (K Units) Table 51. Europe Antidiabetic Biguanides Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific Antidiabetic Biguanides Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific Antidiabetic Biguanides Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific Antidiabetic Biguanides Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa Antidiabetic Biguanides Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa Antidiabetic Biguanides Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa Antidiabetic Biguanides Sales by Country (2027-2032) & (K Units) Table 58. Global Antidiabetic Biguanides Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Antidiabetic Biguanides Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Antidiabetic Biguanides Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Antidiabetic Biguanides Revenue Market Share by Region (2021-2026) Table 62. Global Antidiabetic Biguanides Revenue Market Share by Region (2027-2032) Table 63. Boehringer Ingelheim Company Information Table 64. Boehringer Ingelheim Business Overview Table 65. Boehringer Ingelheim Antidiabetic Biguanides Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Boehringer Ingelheim Antidiabetic Biguanides Product Portfolio Table 67. Boehringer Ingelheim Recent Development Table 68. Bristol-Myers Squibb Company Information Table 69. Bristol-Myers Squibb Business Overview Table 70. Bristol-Myers Squibb Antidiabetic Biguanides Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Bristol-Myers Squibb Antidiabetic Biguanides Product Portfolio Table 72. Bristol-Myers Squibb Recent Development Table 73. Novo Nordisk Company Information Table 74. Novo Nordisk Business Overview Table 75. Novo Nordisk Antidiabetic Biguanides Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Novo Nordisk Antidiabetic Biguanides Product Portfolio Table 77. Novo Nordisk Recent Development Table 78. Servier Laboratories Company Information Table 79. Servier Laboratories Business Overview Table 80. Servier Laboratories Antidiabetic Biguanides Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Servier Laboratories Antidiabetic Biguanides Product Portfolio Table 82. Servier Laboratories Recent Development Table 83. AstraZeneca Company Information Table 84. AstraZeneca Business Overview Table 85. AstraZeneca Antidiabetic Biguanides Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. AstraZeneca Antidiabetic Biguanides Product Portfolio Table 87. AstraZeneca Recent Development Table 88. GlaxoSmithKline Company Information Table 89. GlaxoSmithKline Business Overview Table 90. GlaxoSmithKline Antidiabetic Biguanides Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. GlaxoSmithKline Antidiabetic Biguanides Product Portfolio Table 92. GlaxoSmithKline Recent Development Table 93. Pfizer Company Information Table 94. Pfizer Business Overview Table 95. Pfizer Antidiabetic Biguanides Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Pfizer Antidiabetic Biguanides Product Portfolio Table 97. Pfizer Recent Development Table 98. Eli Lilly Company Information Table 99. Eli Lilly Business Overview Table 100. Eli Lilly Antidiabetic Biguanides Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Eli Lilly Antidiabetic Biguanides Product Portfolio Table 102. Eli Lilly Recent Development Table 103. Merck & Co Company Information Table 104. Merck & Co Business Overview Table 105. Merck & Co Antidiabetic Biguanides Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Merck & Co Antidiabetic Biguanides Product Portfolio Table 107. Merck & Co Recent Development Table 108. Sanofi Company Information Table 109. Sanofi Business Overview Table 110. Sanofi Antidiabetic Biguanides Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Sanofi Antidiabetic Biguanides Product Portfolio Table 112. Sanofi Recent Development Table 113. Takeda Pharmaceuticals Company Information Table 114. Takeda Pharmaceuticals Business Overview Table 115. Takeda Pharmaceuticals Antidiabetic Biguanides Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Takeda Pharmaceuticals Antidiabetic Biguanides Product Portfolio Table 117. Takeda Pharmaceuticals Recent Development Table 118. Key Raw Materials Table 119. Raw Materials Key Suppliers Table 120. Antidiabetic Biguanides Distributors List Table 121. Antidiabetic Biguanides Customers List Table 122. Research Programs/Design for This Report Table 123. Authors List of This Report Table 124. Secondary Sources Table 125. Primary Sources List of Figures Figure 1. Antidiabetic Biguanides Product Image Figure 2. Global Antidiabetic Biguanides Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antidiabetic Biguanides Market Size (2021-2032) & (US$ Million) Figure 4. Global Antidiabetic Biguanides Sales (2021-2032) & (K Units) Figure 5. Global Antidiabetic Biguanides Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Antidiabetic Biguanides Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Metformin IR Image Figure 9. Metformin SR Image Figure 10. Global Antidiabetic Biguanides Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Antidiabetic Biguanides Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Antidiabetic Biguanides Sales Market Share by Type (2021-2032) Figure 13. Global Antidiabetic Biguanides Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Antidiabetic Biguanides Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Antidiabetic Biguanides Revenue Market Share by Type (2021-2032) Figure 16. Hospitals Image Figure 17. Clinics Image Figure 18. Other Image Figure 19. Global Antidiabetic Biguanides Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Antidiabetic Biguanides Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Antidiabetic Biguanides Sales Market Share by Application (2021-2032) Figure 22. Global Antidiabetic Biguanides Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Antidiabetic Biguanides Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Antidiabetic Biguanides Revenue Market Share by Application (2021-2032) Figure 25. North America Antidiabetic Biguanides Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America Antidiabetic Biguanides Sales Market Share by Country (2021-2032) Figure 27. U.S. Antidiabetic Biguanides Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada Antidiabetic Biguanides Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico Antidiabetic Biguanides Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Antidiabetic Biguanides Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Antidiabetic Biguanides Sales Market Share by Country (2021-2032) Figure 32. Germany Antidiabetic Biguanides Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France Antidiabetic Biguanides Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. Antidiabetic Biguanides Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy Antidiabetic Biguanides Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands Antidiabetic Biguanides Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Antidiabetic Biguanides Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Antidiabetic Biguanides Sales Market Share by Country (2021-2032) Figure 39. China Antidiabetic Biguanides Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan Antidiabetic Biguanides Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea Antidiabetic Biguanides Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia Antidiabetic Biguanides Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India Antidiabetic Biguanides Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia Antidiabetic Biguanides Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Antidiabetic Biguanides Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Antidiabetic Biguanides Sales Market Share by Country (2021-2032) Figure 47. Brazil Antidiabetic Biguanides Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa Antidiabetic Biguanides Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia Antidiabetic Biguanides Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey Antidiabetic Biguanides Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina Antidiabetic Biguanides Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE Antidiabetic Biguanides Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt Antidiabetic Biguanides Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile Antidiabetic Biguanides Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global Antidiabetic Biguanides Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Antidiabetic Biguanides Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Antidiabetic Biguanides Revenue (2021-2032) & (US$ Million) Figure 58. North America Antidiabetic Biguanides Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Antidiabetic Biguanides Revenue (2021-2032) & (US$ Million) Figure 60. Europe Antidiabetic Biguanides Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Antidiabetic Biguanides Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Antidiabetic Biguanides Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Antidiabetic Biguanides Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Antidiabetic Biguanides Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Antidiabetic Biguanides Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Antidiabetic Biguanides Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Metformin IR
  • Metformin SR
Applications
  • Hospitals
  • Clinics
  • Other
Companies covered
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Novo Nordisk
  • Servier Laboratories
  • AstraZeneca
  • GlaxoSmithKline
  • Pfizer
  • Eli Lilly
  • Merck & Co
  • Sanofi
  • Takeda Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Antidiabetic Biguanides Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Antidiabetic Biguanides Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Antidiabetic Biguanides Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Antidiabetic Biguanides Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Antidiabetic Biguanides Market Dynamics
  1. 2.1 Antidiabetic Biguanides Industry Trends
  2. 2.2 Antidiabetic Biguanides Industry Drivers
  3. 2.3 Antidiabetic Biguanides Industry Opportunities and Challenges
  4. 2.4 Antidiabetic Biguanides Industry Restraints
3 Antidiabetic Biguanides Market by Manufacturers
  1. 3.1 Global Antidiabetic Biguanides Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Antidiabetic Biguanides Sales by Manufacturers (2021-2026)
  3. 3.3 Global Antidiabetic Biguanides Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Antidiabetic Biguanides Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Antidiabetic Biguanides Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Antidiabetic Biguanides Manufacturers, Product Type & Application
  7. 3.7 Global Antidiabetic Biguanides Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Antidiabetic Biguanides Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Antidiabetic Biguanides Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Antidiabetic Biguanides Tier 1, Tier 2, and Tier 3
4 Antidiabetic Biguanides Market by Type
  1. 4.1 Antidiabetic Biguanides Type Introduction
  2. 4.1.1 Metformin IR
  3. 4.1.2 Metformin SR
  4. 4.2 Global Antidiabetic Biguanides Sales by Type
  5. 4.2.1 Global Antidiabetic Biguanides Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Antidiabetic Biguanides Sales by Type (2021-2032)
  7. 4.2.3 Global Antidiabetic Biguanides Sales Market Share by Type (2021-2032)
  8. 4.3 Global Antidiabetic Biguanides Revenue by Type
  9. 4.3.1 Global Antidiabetic Biguanides Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Antidiabetic Biguanides Revenue by Type (2021-2032)
  11. 4.3.3 Global Antidiabetic Biguanides Revenue Market Share by Type (2021-2032)
5 Antidiabetic Biguanides Market by Application
  1. 5.1 Antidiabetic Biguanides Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Other
  5. 5.2 Global Antidiabetic Biguanides Sales by Application
  6. 5.2.1 Global Antidiabetic Biguanides Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Antidiabetic Biguanides Sales by Application (2021-2032)
  8. 5.2.3 Global Antidiabetic Biguanides Sales Market Share by Application (2021-2032)
  9. 5.3 Global Antidiabetic Biguanides Revenue by Application
  10. 5.3.1 Global Antidiabetic Biguanides Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Antidiabetic Biguanides Revenue by Application (2021-2032)
  12. 5.3.3 Global Antidiabetic Biguanides Revenue Market Share by Application (2021-2032)
6 Global Antidiabetic Biguanides Sales by Region
  1. 6.1 Global Antidiabetic Biguanides Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antidiabetic Biguanides Sales by Region (2021-2032)
  3. 6.2.1 Global Antidiabetic Biguanides Sales by Region (2021-2026)
  4. 6.2.2 Global Antidiabetic Biguanides Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Antidiabetic Biguanides Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Antidiabetic Biguanides Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Antidiabetic Biguanides Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Antidiabetic Biguanides Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Antidiabetic Biguanides Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Antidiabetic Biguanides Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Antidiabetic Biguanides Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Antidiabetic Biguanides Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Antidiabetic Biguanides Revenue by Region
  1. 7.1 Global Antidiabetic Biguanides Revenue by Region
  2. 7.1.1 Global Antidiabetic Biguanides Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Antidiabetic Biguanides Revenue by Region (2021-2026)
  4. 7.1.3 Global Antidiabetic Biguanides Revenue by Region (2027-2032)
  5. 7.1.4 Global Antidiabetic Biguanides Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Antidiabetic Biguanides Revenue (2021-2032)
  8. 7.2.2 North America Antidiabetic Biguanides Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Antidiabetic Biguanides Revenue (2021-2032)
  11. 7.3.2 Europe Antidiabetic Biguanides Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Antidiabetic Biguanides Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Antidiabetic Biguanides Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Antidiabetic Biguanides Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Antidiabetic Biguanides Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Boehringer Ingelheim
  2. 8.1.1 Boehringer Ingelheim Company Information
  3. 8.1.2 Boehringer Ingelheim Business Overview
  4. 8.1.3 Boehringer Ingelheim Antidiabetic Biguanides Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Boehringer Ingelheim Antidiabetic Biguanides Product Portfolio
  6. 8.1.5 Boehringer Ingelheim Recent Developments
  7. 8.2 Bristol-Myers Squibb
  8. 8.2.1 Bristol-Myers Squibb Company Information
  9. 8.2.2 Bristol-Myers Squibb Business Overview
  10. 8.2.3 Bristol-Myers Squibb Antidiabetic Biguanides Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bristol-Myers Squibb Antidiabetic Biguanides Product Portfolio
  12. 8.2.5 Bristol-Myers Squibb Recent Developments
  13. 8.3 Novo Nordisk
  14. 8.3.1 Novo Nordisk Company Information
  15. 8.3.2 Novo Nordisk Business Overview
  16. 8.3.3 Novo Nordisk Antidiabetic Biguanides Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novo Nordisk Antidiabetic Biguanides Product Portfolio
  18. 8.3.5 Novo Nordisk Recent Developments
  19. 8.4 Servier Laboratories
  20. 8.4.1 Servier Laboratories Company Information
  21. 8.4.2 Servier Laboratories Business Overview
  22. 8.4.3 Servier Laboratories Antidiabetic Biguanides Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Servier Laboratories Antidiabetic Biguanides Product Portfolio
  24. 8.4.5 Servier Laboratories Recent Developments
  25. 8.5 AstraZeneca
  26. 8.5.1 AstraZeneca Company Information
  27. 8.5.2 AstraZeneca Business Overview
  28. 8.5.3 AstraZeneca Antidiabetic Biguanides Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 AstraZeneca Antidiabetic Biguanides Product Portfolio
  30. 8.5.5 AstraZeneca Recent Developments
  31. 8.6 GlaxoSmithKline
  32. 8.6.1 GlaxoSmithKline Company Information
  33. 8.6.2 GlaxoSmithKline Business Overview
  34. 8.6.3 GlaxoSmithKline Antidiabetic Biguanides Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 GlaxoSmithKline Antidiabetic Biguanides Product Portfolio
  36. 8.6.5 GlaxoSmithKline Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Antidiabetic Biguanides Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Antidiabetic Biguanides Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Eli Lilly
  44. 8.8.1 Eli Lilly Company Information
  45. 8.8.2 Eli Lilly Business Overview
  46. 8.8.3 Eli Lilly Antidiabetic Biguanides Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Eli Lilly Antidiabetic Biguanides Product Portfolio
  48. 8.8.5 Eli Lilly Recent Developments
  49. 8.9 Merck & Co
  50. 8.9.1 Merck & Co Company Information
  51. 8.9.2 Merck & Co Business Overview
  52. 8.9.3 Merck & Co Antidiabetic Biguanides Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Merck & Co Antidiabetic Biguanides Product Portfolio
  54. 8.9.5 Merck & Co Recent Developments
  55. 8.10 Sanofi
  56. 8.10.1 Sanofi Company Information
  57. 8.10.2 Sanofi Business Overview
  58. 8.10.3 Sanofi Antidiabetic Biguanides Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Sanofi Antidiabetic Biguanides Product Portfolio
  60. 8.10.5 Sanofi Recent Developments
  61. 8.11 Takeda Pharmaceuticals
  62. 8.11.1 Takeda Pharmaceuticals Company Information
  63. 8.11.2 Takeda Pharmaceuticals Business Overview
  64. 8.11.3 Takeda Pharmaceuticals Antidiabetic Biguanides Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Takeda Pharmaceuticals Antidiabetic Biguanides Product Portfolio
  66. 8.11.5 Takeda Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Antidiabetic Biguanides Value Chain Analysis
  2. 9.1.1 Antidiabetic Biguanides Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Antidiabetic Biguanides Production Mode & Process
  6. 9.2 Antidiabetic Biguanides Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Antidiabetic Biguanides Distributors
  9. 9.2.3 Antidiabetic Biguanides Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst